Advertisement
UK markets open in 3 hours 13 minutes

  • NIKKEI 225

    38,311.63
    +237.65 (+0.62%)
     

  • HANG SENG

    18,830.62
    +292.81 (+1.58%)
     

  • CRUDE OIL

    79.75
    +0.49 (+0.62%)
     

  • GOLD FUTURES

    2,359.40
    +19.10 (+0.82%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • Bitcoin GBP

    50,209.33
    +980.05 (+1.99%)
     

  • CMC Crypto 200

    1,351.72
    +51.62 (+3.97%)
     

  • NASDAQ Composite

    16,346.26
    +43.46 (+0.27%)
     

  • UK FTSE All Share

    4,558.37
    +14.13 (+0.31%)
     
Money:

Best UK mortgage deals of the week

As Bank of England holds interest rates, here's what high street banks are offering home buyers

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, Inc.
·1-min read
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc.

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.

  • Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place virtually on April 8, 2024 at 8:00a.m EDT. A live webcast of the fireside chat will be available through this link, and also available on the “Investors + Media” section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

  • Management will also participate in the Piper Sandler Spring Biopharma Symposium, taking place in Boston, MA on April 16-17, 2024.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

ADVERTISEMENT
CONTACT: Investor Contact:  Praxis Precision Medicines  investors@praxismedicines.com  857-702-9452    Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576